

MT2023-29: Long-term Follow-up of Subjects With Sickle Cell Disease Treated With ExVivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Not specified

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 2 to 53 years old - treated with a clinical product to Sickle Cell Disease (SCD) in clinical study sponsored by bluebird bio-

Exclusion Criteria:

- there are no exclusion criteria for this study

Conditions & Interventions

Conditions:

Rare Diseases, Blood Disorders

Keywords:

SCD, Sickle Cell, Clinics and Surgery Center (CSC)

More Information

Description: The purpose of this study is to evaluate the long-term safety and ability of a transplant with gene modified stem cells (autologous stem cell transplant) to treat sickle cell disease. Participants must have received investigational gene therapy with bb1111 in a clinical study sponsored by bluebird bio. There is no additional treatment associated with this study as this is a long-term follow-up study.

Study Contact: Ashish Gupta - gupta461@umn.edu

Principal Investigator: Ashish Gupta

IRB

Number: STUDY00020842

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.